State Street Corp Actinium Pharmaceuticals, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 602,649 shares of ATNM stock, worth $849,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares

602,649

Previous 609,673 1.15%

Holding current value

$849,735

Previous $4.51 Million 74.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.72 - $8.0 $12,081 - $56,192	-7,024 Reduced 1.15%	602,649 $1.13 Million
Q2 2024 Aug 14, 2024	BUY	$6.56 - $9.89 $385,911 - $581,808	58,828 Added 10.68%	609,673 $4.51 Million
Q1 2024 May 15, 2024	BUY	$5.0 - $9.2 $220,015 - $404,827	44,003 Added 8.68%	550,845 $4.31 Million
Q4 2023 Feb 14, 2024	SELL	$4.02 - $6.08 $64,922 - $98,192	-16,150 Reduced 3.09%	506,842 $2.57 Million
Q3 2023 Nov 14, 2023	BUY	$5.91 - $7.37 $244,017 - $304,299	41,289 Added 8.57%	522,992 $3.1 Million
Q2 2023 Aug 14, 2023	BUY	$7.15 - $9.39 $2.76 Million - $3.62 Million	385,688 Added 401.7%	481,703 $3.57 Million
Q1 2023 May 15, 2023	BUY	$8.51 - $14.26 $65,527 - $109,802	7,700 Added 8.72%	96,015 $907,000
Q4 2022 Feb 14, 2023	BUY	$7.05 - $14.41 $92,355 - $188,771	13,100 Added 17.42%	88,315 $940,000
Q2 2022 Aug 15, 2022	BUY	$4.71 - $7.11 $57,462 - $86,742	12,200 Added 19.36%	75,215 $362,000
Q1 2022 May 16, 2022	BUY	$4.57 - $6.4 $32,095 - $44,947	7,023 Added 12.54%	63,015 $322,000
Q4 2021 Feb 14, 2022	BUY	$6.01 - $8.8 $4,207 - $6,160	700 Added 1.27%	55,992 $337,000
Q2 2021 Aug 16, 2021	BUY	$7.01 - $8.63 $387,596 - $477,169	55,292 New	55,292 $437,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

8.32M

Call Options Held

65.2K

Put Options Held

21.7K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $35.5M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Actinium Pharmaceuticals, Inc. Transaction History